Breaking Barriers: The Benefits Of Being A Swiss Biotech
The lack of distractions from a large domestic market and a close proximity of research centers are just two advantages for the flourishing Swiss biotech sector, which enjoyed a bumper year in 2021, says its industry association.
You may also be interested in...
The major will use the biotech’s brain cell-focused platform technology to discover new targets for Alzheimer’s disease.
David Caumartin is well versed in the both the benefits and drawbacks of being a France-based medtech innovator, having spent almost three decades in the local industry. The VP of France Biotech spoke to Medtech Insight about the new opportunities there to be seized, and the pitfalls to avoid.
The UK major has teamed up with the US biotech to develop the latter’s HER-2 targeted antibody-drug conjugate, a couple of years after the approval of Blenrep, in what is becoming an increasingly competitive space.